# ANTICOAGULATION

Therapeutic indications: venous thromboembolic disease - DVT and PE.

Prophylactic indications:

- prevention of DVT/PE in high risk patients
	- e.g. post-op
- prevention of stroke
	- e.g. chronic AF, prosthetic heart valve

### HEPARIN

#### LOW MOLECULAR WEIGHT HEPARIN

**Preferred option for prevention + treatment of VTE and in ACS.**

e.g. dalteparin, enoxaparin, tinzaparin

**Mechanism: inactivates factor Xa (but not thrombin).**

Given SC.

Molecular weight ~5000 Daltons (cf UFH).

Given once or twice daily, no lab monitoring required:

- half-life 2-4x standard heparin
- response more predicatable
- can be given less frequently/not monitored

Accumulates in renal failure so lower doses used in prophylaxis, or UFH given for therapeutic doses.


#### UNFRACTIONATED HEPARIN

**Mechanism: inhibits thrombin, factor Xa and IXa.** 

Glycosaminoglycan, which binds antithrombin (an endogenous inhibitor of coagulation), increasing its inhibition ability.

Given IV or SC.

Molecular weight ~13,000 Daltons (cf LMWH).

Rapid onset, short half life.

Monitor and adjust dose with APTT: requires lab monitoring.

Protamine sulfate counteracts UFH.

#### SIDE EFFECTS

- increased **bleeding**, e.g. at op site, GI, intracranial

- heparin-induced **thrombocytopenia** (HIT)

- **osteoporosis** with long-term use

HIT + osteoporosis less common with LMWH than UFH.

Beware hyperkalaemia.


#### CONTRAINDICATIONS

- bleeding disorders

- platelets <60 x10^9/L

- previous HIT

- peptic ulcer

- cerebral haemorrhage

- severe hypertension

- neurosurgery


### WARFARIN

**Long-term anticoagulation.**

PO OD.

Narrow therapeutic range, measured by INR - target INR depends on indication for anticoagulation (see below).

**Mechanism**: inhibits reductase enzyme responsible for regenerating the active form of vitamin K - produces state analagous to vitamin K deficiency.

#### INDICATIONS & TARGET INR 

**PE and DVT**: 2-3, 3.5 if recurrent.

**Atrial fibrillation** (for stroke prevention): 2-3

**Prosthetic metallic heart valves** (for stroke prevention): 3-4

#### CONTRAINDICATIONS

- peptic ulcer

- bleeding disorders

- severe hypertension

- pregnancy: teratogenic

Use with caution in elderly + previous GI bleeds.

#### DURATION

Duration of rx for DVT/PE:

- if cause will go away, e.g. post-op immobility
	- 6/52 for below knee DVT
	- 3/12 for above knee DVT + PE
- at least 6/12 if no cause found
- indefinitely for identified, enduring causes e.g. thrombophilia

#### HIGH INR

INR | Recommended action
--- | ---
4.5-6 | reduce warfarin dose or omit; restart when INR <5
6-8 | stop warfarin; restart when INR <5
8+, no or minor bleed, or epistaxis | if no bleeding: stop warfarin. If risk factors for bleeding, **0.5-2.5mg vitamin K PO**. Check INR daily.
Any major bleed (incl intracranial haemorrhage) | stop warfarin. Give **prothrombin complex concentrate 50 U/kg** (or **FFP** if unavailable). **5-10mg vitamin K IV** slowly.


### OTHERS

**Fondaparinux**: pentasaccharide Xa inhibitor. Sometimes used prophylactically instead of LMWH.

**NOACs**:

- new oral anticoagulants
- no need for monitoring
- but no antidote
- **rivaroxaban** + **apixaban**: factor Xa inhibitors
- **dabigatran**: direct thrombin inhibitor